Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck

被引:236
|
作者
Hustinx, R
Smith, RJ
Benard, F
Rosenthal, DI
Machtay, M
Farber, LA
Alavi, A
机构
[1] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA 19104 USA
[2] Univ Penn Hlth Syst, Dept Radiat Oncol, Philadelphia, PA USA
基金
英国医学研究理事会;
关键词
positron emission tomography; fluorine-18; fluorodeoxyglucose; head and neck cancer; inflammation; standardised uptake value;
D O I
10.1007/s002590050593
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) studies imaging FDG PET imaging is used to detect and stage head and neck cancers. However, the variable physiologic uptake of FDG in different normal structures as well as at inflammatory sites may either obscure a tumor focus or be falsely interpreted to represent tumor activity, Twenty-one patients (9 men, 12 women, median age 59) were scanned serially at two time points, one at 70 min (range 47-112) and the second at 98 min (77-142) after the intravenous injection of 4.3 MBq/kg of FDG. The mean interval between emission scans was 28 min (13-49). Transmission scans were performed and regions of interest (ROIs) were overlayed on the fully corrected images. Standardiued uptake values (SUVs) were generated for the cerebellum, tongue, larynx, every lesion, and a matched contralateral site. Follow-up and pathologic studies revealed 18 squamous cell carcinomas and nine inflammatory or infectious lesions. Tumor SUVs were 4.0+/-1.6 (mean +/- SD) for the first scan and 4.5+/-2.2 for the second scan. Contralateral SUVs were 1.2+/-0.5 and 1.1+/-0.5 for the two scans. Tumor SUVs increased by 12%+/-12% as compared with a 5%+/-17% decrease for contralateral sites (P<0.05). SUVs for inflammatory sites (2.0+/-0.7 and 2.0+/-0.9), cerebellum (4.2+/-1.3 and 4.3+/-1.4), tongue (1.8+/-0.4 and 1.9+/-0.5) and larynx (1.5+/-0.6 and 1.5+/-0.6) remained constant over time (+0.6%, +2.8%, +1.4%, and -2.4%; P<0.05 when compared with tumor SUV changes). The ratio tumor/contralateral SUV increased by 23%+/-29% over time while this ratio for inflamed sites increased by only 5%+/-15% (P=0.07). The time interval between scans correlated with increase in SUV for tumors (r=0.55, P<0.05) but not for any of the other ROIs. Separation was superior when studies were performed more than 30 min apart (P<0.05). These preliminary data suggest that dual time point imaging compatible with a clinical study protocol is helpful in differentiating malignant lesions from inflammation and normal tissues, especially when separated by a sufficient time interval.
引用
收藏
页码:1345 / 1348
页数:4
相关论文
共 34 条
  • [1] Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck
    Roland Hustinx
    Robin J. Smith
    Francois Benard
    David I. Rosenthal
    Mitchell Machtay
    Leonard A. Farber
    Abass Alavi
    European Journal of Nuclear Medicine, 1999, 26 : 1345 - 1348
  • [2] Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer
    Boerner, AR
    Weckesser, M
    Herzog, H
    Schmitz, T
    Audretsch, W
    Nitz, U
    Bender, HG
    Mueller-Gaertner, HW
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (03) : 226 - 230
  • [3] Prognostic value of fluorine-18 fluorodeoxyglucose positron-emission tomography imaging in patients with head and neck squamous cell carcinoma
    Querellou, Solene
    Abgral, Ronan
    Le Roux, Pierre-Yves
    Nowak, Emmanuel
    Valette, Gerald
    Potard, Gael
    Le Duc-Pennec, Alexandra
    Cavarec, Marie-Beatrice
    Marianovski, Remi
    Salauen, Pierre-Yves
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2012, 34 (04): : 462 - 468
  • [4] Imaging of atherosclerotic aorta of rabbit model by detection of plaque inflammation with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography
    Zhao Quan-ming
    Feng Ting-ting
    Zhao Xin
    Xu Zhan-min
    Liu Yu
    Li De-peng
    Li Li-qin
    Su Gong
    Zhang Xiao-xia
    CHINESE MEDICAL JOURNAL, 2011, 124 (06) : 911 - 917
  • [5] Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation
    Osborne, Michael T.
    Hulten, Edward A.
    Murthy, Venkatesh L.
    Skali, Hicham
    Taqueti, Viviany R.
    Dorbala, Sharmila
    DiCarli, Marcelo F.
    Blankstein, Ron
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 86 - 99
  • [6] Fluorine-18 fluorodeoxyglucose positron emission tomography for cardiac sarcoidosis-is it time to consider a new radiotracer?
    Christopoulos, Georgios
    Chareonthaitawee, Panithaya
    EJNMMI RESEARCH, 2017, 7
  • [7] Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation
    Michael T. Osborne
    Edward A. Hulten
    Venkatesh L. Murthy
    Hicham Skali
    Viviany R. Taqueti
    Sharmila Dorbala
    Marcelo F. DiCarli
    Ron Blankstein
    Journal of Nuclear Cardiology, 2017, 24 : 86 - 99
  • [8] Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results
    Stokkel, MPM
    de Klerk, JHM
    Zelissen, PMJ
    Koppeschaar, HPF
    van Rijk, PP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (12) : 1606 - 1609
  • [9] Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma
    Eigtved, A
    Andersson, AP
    Dahlstrom, K
    Rabol, A
    Jensen, M
    Holm, S
    Sorensen, SS
    Drzewiecki, KT
    Hojgaard, L
    Friberg, L
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (01) : 70 - 75
  • [10] Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer
    Pai, M
    Park, CH
    Suh, JH
    Koh, JH
    CLINICAL NUCLEAR MEDICINE, 1999, 24 (07) : 495 - 500